Bayer Highlights Promising OCEANIC-STROKE Trial Results for Asundexian in Recurrent Stroke Prevention

Asundexian Reduces Recurrent Stroke Risk by 26% Compared to Placebo in Phase III Trial

Feb. 6, 2026 at 5:47pm

Got story updates? Submit your updates here. ›

Bayer Aktiengesellschaft presented results from its OCEANIC-STROKE phase III trial, showcasing the potential of its investigational drug asundexian to significantly reduce the risk of recurrent strokes. The trial found that asundexian, a once-daily oral Factor XIa inhibitor, cut the risk of ischemic stroke by 26% compared to placebo in patients with a recent non-cardioembolic ischemic stroke or high-risk TIA. The safety profile of asundexian was also favorable, with no increase in major bleeding events versus placebo.

Why it matters

Stroke remains a major global health burden, with recurrent strokes being particularly common and often more severe. Current treatment options for secondary stroke prevention have seen limited progress in recent decades, making the positive results from the OCEANIC-STROKE trial an important potential advancement in this area. Reducing the risk of recurrent strokes could significantly improve outcomes for stroke survivors and ease the substantial economic strain that strokes place on healthcare systems worldwide.

The details

The OCEANIC-STROKE trial enrolled over 12,000 patients with a recent non-cardioembolic ischemic stroke or high-risk TIA. Participants were randomized 1:1 to receive either asundexian 50 mg once daily or placebo, on top of planned single or dual antiplatelet therapy. The primary efficacy endpoint was time to first ischemic stroke, while the primary safety endpoint was time to first ISTH major bleeding event. Asundexian demonstrated a 26% reduction in the risk of ischemic stroke compared to placebo, with consistent benefits seen across secondary endpoints like all stroke, MACE, and disabling or fatal stroke. Importantly, there was no increase in major bleeding or other safety concerns with asundexian.

  • The OCEANIC-STROKE trial was conducted at 702 sites across 37 countries.
  • Participants were enrolled within 72 hours of symptom onset.

The players

Bayer Aktiengesellschaft

A global life science company that operates in the Pharmaceuticals, Consumer Health, and Crop Science segments.

Ashkan Shoamanesh

Co-principal investigator of the OCEANIC-STROKE trial and researcher at McMaster University.

Christoph Koenen

Head of clinical development and operations at Bayer.

Jan Voss

Bayer representative who discussed commercial considerations for asundexian.

Alexander Seidler

Bayer representative who participated in the investor webinar.

Got photos? Submit your photos here. ›

What they’re saying

“Stroke remains a major global health burden, citing more than 100 million stroke survivors worldwide and an estimated 12 million new strokes each year.”

— Christoph Koenen, Head of clinical development and operations at Bayer (marketbeat.com)

“Preventing recurrent strokes could reduce economic strain and free healthcare resources, while also emphasizing that bleeding events can be cost drivers and affect patient persistence.”

— Jan Voss, Bayer representative (marketbeat.com)

What’s next

Bayer plans to present a landmark analysis of the OCEANIC-STROKE trial at the European Stroke Organization Congress (ESOC) in May 2026. The company is also in active discussions with health authorities globally to accelerate approvals for asundexian.

The takeaway

The positive results from the OCEANIC-STROKE trial for asundexian represent a potentially significant advancement in the treatment of recurrent strokes, an area with limited progress in recent decades. If approved, asundexian could help reduce the substantial health and economic burden of strokes worldwide.